https://www.pharmaradar360.com/article/sommarenkat-jenny-nilsson-skadespelare-strosa-i-charmiga-gamla-stan-bc1b2f8429766ba7Pharma Surgeen2026-07-25T07:23:47.000ZSommarenkät: Jenny Nilsson, skådespelare – Strosa i charmiga gamla stanhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-cardiac-biotech-solutions-inc-otc-cbsc-b2a828ab53737672Pharma Surgeen2026-07-25T06:41:20.000ZEnterprise value to EBIT forward of Cardiac Biotech Solutions Inc. – OTC:CBSChttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-us-will-release-its-earnings-report-on-july-30-fb8a2164d1d70016Pharma Surgeen2026-07-25T05:13:03.000ZTakeda Pharmaceutical (TAK.US) will release its earnings report on July 30.https://www.pharmaradar360.com/article/fda-panel-gives-nod-to-six-controversial-peptides-f02d20943de4c6aaPharma Surgeen2026-07-25T04:33:14.000ZFDA panel gives nod to six controversial peptideshttps://www.pharmaradar360.com/article/u-s-ipo-weekly-recap-crispr-biotech-pops-44-as-more-names-join-the-ipo-pipeline-98c60f17476a8d94Pharma Surgeen2026-07-25T04:30:00.000ZU.S. IPO Weekly Recap: CRISPR Biotech Pops 44% As More Names Join The IPO Pipelinehttps://www.pharmaradar360.com/article/bicara-s-cancer-drug-enters-crucial-trial-phase-says-ceo-claire-mazumdar-504e20a964248910Pharma Surgeen2026-07-25T03:41:54.000ZBicara's cancer drug enters crucial trial phase, says CEO Claire Mazumdarhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-stock-sees-margin-improvement-narrative-backed-e52ce20734007004Pharma Surgeen2026-07-25T03:38:58.000ZWest Pharmaceutical Services (WST) Stock Sees Margin Improvement Narrative Backed By Q2 2026 Resultshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-stock-sees-margin-improvement-narrative-backed-b56c0ea206934abePharma Surgeen2026-07-25T03:38:57.000ZWest Pharmaceutical Services (WST) Stock Sees Margin Improvement Narrative Backed By Q2 2026 Resultshttps://www.pharmaradar360.com/article/chugai-pharmaceutical-chgcf-reports-strong-first-half-earnings-a95d97db44dffa89Pharma Surgeen2026-07-25T03:33:45.000ZChugai Pharmaceutical (CHGCF) Reports Strong First Half Earningshttps://www.pharmaradar360.com/article/jiangxi-synergy-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-300636-61e51cf9a5e886f8Pharma Surgeen2026-07-25T03:11:26.000ZJiangxi Synergy Pharmaceutical Co. Ltd. Class A Revenue Breakdown – SZSE:300636https://www.pharmaradar360.com/article/scribe-therapeutics-ipo-jumps-44-targets-heart-disease-1b24b3e8635ebe30Pharma Surgeen2026-07-25T02:45:00.000ZScribe Therapeutics IPO Jumps 44%, Targets Heart Diseasehttps://www.pharmaradar360.com/article/beijing-beilu-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-300016-a1c23937b621a7b7Pharma Surgeen2026-07-25T02:07:46.000ZBeijing Beilu Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SZSE:300016https://www.pharmaradar360.com/article/veraxa-biotech-ag-nasdaq-vrxa-appoints-christoph-erkel-as-chief-scientific-offic-a810c5e9b7181078Pharma Surgeen2026-07-25T02:04:00.000ZVERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officerhttps://www.pharmaradar360.com/article/this-week-in-boomtown-aviation-industry-in-ohio-affordable-housing-future-of-bio-51d5297eeb42b45bPharma Surgeen2026-07-25T01:39:00.000ZThis Week in Boomtown: Aviation industry in Ohio; affordable housing; future of biotechhttps://www.pharmaradar360.com/article/proprietary-biobotanical-microemulsion-technologies-c3b98d4fa2412c22Pharma Surgeen2026-07-25T01:33:50.000ZProprietary Biobotanical Microemulsion Technologieshttps://www.pharmaradar360.com/article/a215380-static-price-chart-kolmar-biotech-inc-kr7215380007-71c724dfe5eec533Pharma Surgeen2026-07-25T01:11:43.000ZA215380: Static price chart | Kolmar BioTech, Inc. | KR7215380007https://www.pharmaradar360.com/article/kolmar-biotech-inc-shareholders-board-members-managers-and-company-profile-kr721-a5992804a39b6a4aPharma Surgeen2026-07-25T01:11:43.000ZKolmar BioTech, Inc.: Shareholders Board Members Managers and Company Profile | KR7215380007https://www.pharmaradar360.com/article/west-pharmaceutical-services-i-wst-stock-forecasts-8708d5e13e78258bPharma Surgeen2026-07-25T00:53:12.000ZWest Pharmaceutical Services, I (WST) Stock Forecastshttps://www.pharmaradar360.com/article/14-new-weight-loss-drugs-8f97f67645d6c678Pharma Surgeen2026-07-25T00:35:24.000Z14 New Weight Loss Drugshttps://www.pharmaradar360.com/article/comparison-of-whole-genome-sequencing-with-clinical-targeted-panel-sequencing-of-cc282f8d705f195bPharma Surgeen2026-07-25T00:00:00.000ZComparison of whole genome sequencing with clinical targeted panel sequencing of metastatic prostate cancer: insights from real-world datahttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-d44e1196fcde3687Pharma Surgeen2026-07-25T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-38278a26ee1f3551Pharma Surgeen2026-07-25T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-6482b13a4d1370c5Pharma Surgeen2026-07-25T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-01ca72eced5bef72Pharma Surgeen2026-07-25T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-a4e67c6176a3de4dPharma Surgeen2026-07-25T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-faf3c0c18f0c1213Pharma Surgeen2026-07-25T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-2e74240a2a8dd266Pharma Surgeen2026-07-25T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-c46025040ac0e5c8Pharma Surgeen2026-07-25T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-c8baab94b67bd9cdPharma Surgeen2026-07-25T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-e8526dc0c79a844fPharma Surgeen2026-07-25T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-d3cc318cea1059b4Pharma Surgeen2026-07-25T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-a177f1e05c6960bdPharma Surgeen2026-07-25T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-b61213986f329bfbPharma Surgeen2026-07-25T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-6feb50b7023d9605Pharma Surgeen2026-07-25T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/25-69-27f176915ad196dePharma Surgeen2026-07-25T00:00:00.000Z25 ก.ค. 69อย. กำชับผู้ประกอบการใช้วัตถุเจือปนอาหารที่มีไนไตรท์ให้ถูกต้อง ตรวจเข้มสถานที่ผลิตอาหารกลุ่มเสี่ยง พร้อมเผยแพร่สื่อแนะนำการใช้อ่านเพิ่มเติม →https://www.pharmaradar360.com/article/quality-of-inpatient-clinical-documentation-a-bed-head-ticket-audit-at-a-tertiar-409bfbd535aae580Pharma Surgeen2026-07-25T00:00:00.000ZQuality of Inpatient Clinical Documentation: A Bed Head Ticket Audit at a Tertiary Care Hospital in Sri Lankahttps://www.pharmaradar360.com/article/balancing-capacities-in-positive-and-transcultural-psychotherapy-a-case-informed-72a75198dbf879dePharma Surgeen2026-07-25T00:00:00.000ZBalancing capacities in Positive and Transcultural Psychotherapy: A case-informed reflection from clinical practicehttps://www.pharmaradar360.com/article/transformations-of-anger-an-integrative-model-for-clinical-work-with-greed-envy-0eaf66544f66cb50Pharma Surgeen2026-07-25T00:00:00.000ZTransformations of anger: An integrative model for clinical work with greed, envy, jealousy, and guilthttps://www.pharmaradar360.com/article/peer-review-report-for-assessing-perception-and-motivation-of-medical-student-co-a50d1fd6a115787aPharma Surgeen2026-07-25T00:00:00.000ZPeer Review Report For: Assessing perception and motivation of medical student concerning clinical learning in the Faculty of Medicine of Sousse (Tunisia) [version 2; peer review: 2 approved with reservations]https://www.pharmaradar360.com/article/role-of-textiles-in-medical-clinical-case-reports-81ff857413019520Pharma Surgeen2026-07-25T00:00:00.000ZRole of Textiles in Medical Clinical Case Reportshttps://www.pharmaradar360.com/article/elmas-s-theory-of-medical-thermodynamics-and-the-fifth-law-of-thermodynamics-bas-60d428b528f369eaPharma Surgeen2026-07-25T00:00:00.000ZELMAS’s Theory of Medical Thermodynamics and the Fifth Law of Thermodynamics Based Closed-Loop Feedback Bio-Robotic Resonance Method and FM Modulated Smart Drug Algorithm in Glioblastoma - Brain Cancer Treatmenthttps://www.pharmaradar360.com/article/clinical-outcomes-and-quality-of-life-after-laparoscopic-nissen-fundoplication-f-856de3bf5fbc554bPharma Surgeen2026-07-25T00:00:00.000ZClinical Outcomes and Quality of Life after Laparoscopic Nissen Fundoplication for Refractory Gastroesophageal Reflux Disease: A Prospective Cohort Study from Vietnamhttps://www.pharmaradar360.com/article/hemorrhagic-hepatic-cysts-mimicking-mucinous-cystic-neoplasm-imaging-features-an-e01701af1c83bc18Pharma Surgeen2026-07-25T00:00:00.000ZHemorrhagic Hepatic Cysts Mimicking Mucinous Cystic Neoplasm: Imaging Features and Clinical Implicationshttps://www.pharmaradar360.com/article/persuasion-in-scientific-journal-articles-exploring-persuasiveness-and-informati-db2370c2ed4a4036Pharma Surgeen2026-07-25T00:00:00.000ZPersuasion in Scientific Journal Articles: Exploring Persuasiveness and Informativeness among Authors and Readershttps://www.pharmaradar360.com/article/associations-between-inflammatory-markers-and-myocardial-injury-in-patients-trea-25f4a357406481c5Pharma Surgeen2026-07-25T00:00:00.000ZAssociations between inflammatory markers and myocardial injury in patients treated with pitavastatin: A retrospective clinical studyhttps://www.pharmaradar360.com/article/xiaoshen-formula-delays-progression-of-diabetic-kidney-disease-and-improves-gluc-62b64e2f7603cc31Pharma Surgeen2026-07-25T00:00:00.000ZXiaoshen formula delays progression of diabetic kidney disease and improves glucose and lipid metabolism: Association with the JAK/STAT pathwayhttps://www.pharmaradar360.com/article/molecular-mechanism-of-ephedrine-regulated-ferroptosis-in-asthma-via-pkm2-acsl4-40d24cfb9778f3cbPharma Surgeen2026-07-25T00:00:00.000ZMolecular mechanism of ephedrine-regulated ferroptosis in asthma via PKM2–ACSL4 lactylationhttps://www.pharmaradar360.com/article/the-influence-of-linc00511-and-mdm2-mdm4-in-lung-carcinoma-implications-for-immu-43b6edc6360053a2Pharma Surgeen2026-07-25T00:00:00.000ZThe influence of LINC00511 and MDM2/MDM4 in lung carcinoma: Implications for immunological therapeutic strategieshttps://www.pharmaradar360.com/article/clinical-applicability-of-whisper-based-automatic-transcription-for-korean-speec-fae4b6d4d324c4c9Pharma Surgeen2026-07-25T00:00:00.000ZClinical Applicability of Whisper-Based Automatic Transcription for Korean Speech Audiometry Sentence Tests in Older Adults with Hearing Losshttps://www.pharmaradar360.com/article/a-preliminary-study-on-the-efficacy-and-safety-of-a-novel-digital-therapeutic-de-6069a228481e368cPharma Surgeen2026-07-25T00:00:00.000ZA Preliminary Study on the Efficacy and Safety of a Novel Digital Therapeutic Device: A Randomized Clinical Trial in South Korean Pediatric Patients With Attention-Deficit/Hyperactivity Disorderhttps://www.pharmaradar360.com/article/effects-of-blue-green-space-exposure-on-psychological-well-being-and-mental-heal-bfb659e1505c9c08Pharma Surgeen2026-07-25T00:00:00.000ZEffects Of Blue-Green Space Exposure On Psychological Well-Being And Mental Health: A Rapid Reviewhttps://www.pharmaradar360.com/article/comparative-analysis-of-weighted-bayesian-belief-network-and-fuzzy-weighted-baye-98d80b7184d26359Pharma Surgeen2026-07-25T00:00:00.000ZComparative Analysis of Weighted Bayesian Belief Network and Fuzzy Weighted Bayesian Belief Network in Clinical Decision Supporthttps://www.pharmaradar360.com/article/impact-of-dual-task-training-vs-single-task-training-on-balance-gait-speed-and-c-49b407a35c00ba96Pharma Surgeen2026-07-25T00:00:00.000ZImpact of Dual task training vs single task training on balance, gait speed and cognitive function in Post stroke patients: A systematic reviewhttps://www.pharmaradar360.com/article/integrative-forensic-modalities-in-disaster-victim-identification-a-comparative-ad1475fd3eb27033Pharma Surgeen2026-07-25T00:00:00.000ZIntegrative Forensic Modalities in Disaster Victim Identification: A Comparative Analytical Study of DNA Profiling, Forensic Odontology, and Digital Forensics in Mass Fatality Incidentshttps://www.pharmaradar360.com/article/predictive-value-of-spermatic-vein-diameter-threshold-and-clinical-factors-for-s-078636b8789de8a9Pharma Surgeen2026-07-25T00:00:00.000ZPredictive Value of Spermatic Vein Diameter Threshold and Clinical Factors for Semen Quality Improvement after Varicocelectomy in Rural Men Aged 30–35 Years: A Prospective Observational Studyhttps://www.pharmaradar360.com/article/enhancing-quality-management-systems-qms-in-clinical-data-management-using-machi-52720f0747ea08f6Pharma Surgeen2026-07-25T00:00:00.000ZEnhancing Quality Management Systems (QMS) in Clinical Data Management using Machine Learning: A Systematic Scoping Review and Proposed Reference Frameworkhttps://www.pharmaradar360.com/article/phytochemical-profiling-quantitative-estimation-isolation-and-characterization-o-7b7148c289fbc53dPharma Surgeen2026-07-25T00:00:00.000ZPHYTOCHEMICAL PROFILING, QUANTITATIVE ESTIMATION, ISOLATION AND CHARACTERIZATION OF BIOACTIVE CONSTITUENTS FROM JUSTICIA BETONICA (L.) AND VIGNA TRILOBATA (L.) VERDC.https://www.pharmaradar360.com/article/development-and-validation-of-a-high-performance-liquid-chromatographic-hplc-met-4c8286c129cdb0fdPharma Surgeen2026-07-25T00:00:00.000ZDevelopment and Validation of a High-Performance Liquid Chromatographic (HPLC) Method for the Simultaneous Estimation of Five Related Pyridine Compounds Using a Mixed-Mode Primesep 100 Column.https://www.pharmaradar360.com/article/gender-and-operative-difficulty-in-laparoscopic-cholecystectomy-2d1a14dc09628404Pharma Surgeen2026-07-25T00:00:00.000ZGENDER AND OPERATIVE DIFFICULTY IN LAPAROSCOPIC CHOLECYSTECTOMYhttps://www.pharmaradar360.com/article/comparative-evaluation-of-external-apical-root-resorption-following-en-masse-ret-d6c81cf132d7e2dePharma Surgeen2026-07-25T00:00:00.000ZComparative Evaluation of External Apical Root Resorption Following En-Masse Retraction Using Conventional Anchorage and Temporary Anchorage Devices: A CBCT Studyhttps://www.pharmaradar360.com/article/clinical-outcomes-and-recurrence-prevention-in-laparoscopic-wells-rectopexy-for-915aa2b64330c2c4Pharma Surgeen2026-07-25T00:00:00.000ZClinical Outcomes and Recurrence Prevention in Laparoscopic Wells Rectopexy for Rectal Prolapse through Mesh Trimming and Fixation Techniqueshttps://www.pharmaradar360.com/article/clinical-significance-of-lymph-node-count-in-colon-cancer-surgery-a-tumour-locat-591deaea176795c3Pharma Surgeen2026-07-25T00:00:00.000ZClinical Significance of Lymph Node Count in Colon Cancer Surgery: A Tumour Location-stratified Prognostic Analysis Based on an Integrated Phase-III Randomized Controlled Trial (JCOG2310AS3)https://www.pharmaradar360.com/article/prediction-of-pathological-complete-response-after-chemoradiation-for-locally-ad-e0ed343f85d7fb76Pharma Surgeen2026-07-25T00:00:00.000ZPrediction of Pathological Complete Response after Chemoradiation for Locally Advanced Rectal Cancer Using Machine Learning with Clinical Features, the INTERCEPTOR Study Preliminary Modelhttps://www.pharmaradar360.com/article/clinical-and-radiographic-outcomes-after-surgical-treatment-of-supination-adduct-5961501abcbbf7c5Pharma Surgeen2026-07-25T00:00:00.000ZClinical and radiographic outcomes after surgical treatment of supination-adduction type ankle fractures in older (≥65 years) and younger (<65 years) patients: a retrospective single-center comparative study in Koreahttps://www.pharmaradar360.com/article/absolute-lt-sup-gt-19-lt-sup-gt-f-qnmr-quantification-of-fluorinated-pharmaceuti-5f0dde94c06553f9Pharma Surgeen2026-07-25T00:00:00.000ZAbsolute <sup>19</sup>F-qNMR Quantification of Fluorinated Pharmaceuticals: Fluorometholone, Flurbiprofen, and Flutamidehttps://www.pharmaradar360.com/article/leveraging-fourier-transform-infrared-spectroscopy-for-community-drug-checking-t-9760e033e9fa17e7Pharma Surgeen2026-07-25T00:00:00.000ZLeveraging fourier-transform infrared spectroscopy for community drug checking to bridge clinical care and harm reduction services: case reporthttps://www.pharmaradar360.com/article/risk-prediction-models-for-venous-thromboembolism-in-the-intensive-care-unit-a-s-2341ba8b1510d69aPharma Surgeen2026-07-25T00:00:00.000ZRisk prediction models for venous thromboembolism in the intensive care unit: a systematic review protocol assessing model performance, risk of bias, and clinical applicabilityhttps://www.pharmaradar360.com/article/preoperative-antibiotics-for-mild-or-moderate-acute-cholecystitis-pommac-study-p-c7a3ad0b1db8306fPharma Surgeen2026-07-25T00:00:00.000ZPreoperative antibiotics for mild or moderate acute cholecystitis (POMMAC): study protocol for a non-inferiority, open-label, randomized controlled trialhttps://www.pharmaradar360.com/article/randomised-placebo-controlled-study-to-assess-the-safety-and-efficacy-of-enteros-6e1649692906a188Pharma Surgeen2026-07-25T00:00:00.000ZRandomised, placebo-controlled study to assess the safety and efficacy of Enterosgel® in the treatment of functional abdominal pain in children and young people (ENTOPIC): study protocol for a clinical trialhttps://www.pharmaradar360.com/article/malaria-diagnosis-practices-in-formal-private-drug-retail-shops-in-the-ho-munici-8ad91c9c36bc8829Pharma Surgeen2026-07-25T00:00:00.000ZMalaria diagnosis practices in formal private drug retail shops in the Ho Municipality, Ghana: a cross-sectional surveyhttps://www.pharmaradar360.com/article/comparison-of-chatgpt-gemini-and-deepseek-responses-to-questions-on-medication-r-b9b236cf6a55dae9Pharma Surgeen2026-07-25T00:00:00.000ZComparison of ChatGPT, Gemini, and DeepSeek responses to questions on medication-related osteonecrosis of the jaw (MRONJ): a comparative analysis of expert-rated clinical quality, readability, response time, and clinical safety riskhttps://www.pharmaradar360.com/article/construction-of-a-clinical-model-for-proximal-caries-via-machine-learning-algori-e4904909d7711207Pharma Surgeen2026-07-25T00:00:00.000ZConstruction of a clinical model for proximal caries via machine learning algorithmshttps://www.pharmaradar360.com/article/effectiveness-of-three-remote-tele-prehabilitation-strategies-in-patients-awaiti-61c5d658afc562fbPharma Surgeen2026-07-25T00:00:00.000ZEffectiveness of three remote tele-prehabilitation strategies in patients awaiting lower limb arthroplasty: a three-arm randomized controlled trialhttps://www.pharmaradar360.com/article/antibiotic-dispensing-practices-and-patterns-of-non-prescription-antibiotic-sale-fe3362e8968f40e8Pharma Surgeen2026-07-25T00:00:00.000ZAntibiotic dispensing practices and patterns of non-prescription antibiotic sales among retail drug outlets in Ghanahttps://www.pharmaradar360.com/article/clinical-features-and-imaging-diagnostic-challenges-of-fetus-in-fetu-associated-cdc897326183728bPharma Surgeen2026-07-25T00:00:00.000ZClinical features and imaging diagnostic challenges of fetus-in-fetu associated with abdominal cryptorchidism: a case reporthttps://www.pharmaradar360.com/article/very-early-onset-inflammatory-bowel-disease-in-jordan-a-single-center-case-serie-62ef6f90126d0e47Pharma Surgeen2026-07-25T00:00:00.000ZVery early onset inflammatory bowel disease in Jordan: a single-center case series of clinical, genetic, and therapeutic featureshttps://www.pharmaradar360.com/article/implementation-strategies-used-in-clinical-practice-guidelines-in-older-adults-m-3483a601a8469c08Pharma Surgeen2026-07-25T00:00:00.000ZImplementation strategies used in clinical practice guidelines in older adults’ mental health and neurocognitive conditions: a scoping reviewhttps://www.pharmaradar360.com/article/clinical-similarity-economic-divergence-cost-effectiveness-and-population-health-03b77fe699463382Pharma Surgeen2026-07-25T00:00:00.000ZClinical similarity, economic divergence: cost-effectiveness and population health implications of dietary, pharmacological, and exercise interventions in older adults with type 2 diabetes: a secondary analysis of a randomized controlled trialhttps://www.pharmaradar360.com/article/qoq-med3-a-multimodal-reasoning-foundation-model-for-clinical-analysis-f6a560829d046aeaPharma Surgeen2026-07-25T00:00:00.000ZQoQ-Med3: a multimodal reasoning foundation model for clinical analysishttps://www.pharmaradar360.com/article/comparison-of-whole-genome-sequencing-with-clinical-targeted-panel-sequencing-of-8a3990326bbe3b08Pharma Surgeen2026-07-25T00:00:00.000ZComparison of whole genome sequencing with clinical targeted panel sequencing of metastatic prostate cancer: insights from real-world datahttps://www.pharmaradar360.com/article/sialorrhea-outcomes-after-sublingual-atropine-in-neurogenic-disorders-evidence-f-45dd74c821568267Pharma Surgeen2026-07-25T00:00:00.000ZSialorrhea Outcomes After Sublingual Atropine in Neurogenic Disorders: Evidence From Randomized Controlled Trialshttps://www.pharmaradar360.com/article/vital-pulp-therapy-from-biological-foundations-to-contemporary-clinical-practice-add7bd036c3a92e8Pharma Surgeen2026-07-25T00:00:00.000ZVital Pulp Therapy: From Biological Foundations to Contemporary Clinical Practice with a Clinical Case Reporthttps://www.pharmaradar360.com/article/extended-depth-of-field-intraocular-lens-for-cataract-after-vitrectomy-for-retin-7818a652b69ffd81Pharma Surgeen2026-07-25T00:00:00.000ZExtended Depth of Field Intraocular Lens for Cataract After Vitrectomy for Retinal Detachment: A Prospective Trialhttps://www.pharmaradar360.com/article/clinical-efficacy-of-a-12-pure-vitamin-c-serum-across-all-skin-phototypes-an-int-c28b95cc41963036Pharma Surgeen2026-07-25T00:00:00.000ZClinical Efficacy of a 12% Pure Vitamin C Serum Across All Skin Phototypes: An Integrated In Vitro–In Vivo Evaluationhttps://www.pharmaradar360.com/article/analysis-of-the-genetic-and-clinical-characteristics-of-18-pfapa-syndrome-patien-62bc5568bbd8420dPharma Surgeen2026-07-25T00:00:00.000ZAnalysis of the Genetic and Clinical Characteristics of 18 PFAPA Syndrome Patients in the Eastern Guangdong Province of Chinahttps://www.pharmaradar360.com/article/liposomal-bupivacaine-in-perioperative-analgesia-a-comprehensive-review-of-clini-d114ae4401a138c4Pharma Surgeen2026-07-25T00:00:00.000ZLiposomal Bupivacaine in Perioperative Analgesia: A Comprehensive Review of Clinical Efficacy, Safety, and Economic Contexthttps://www.pharmaradar360.com/article/dna-repair-epigenetic-dysregulation-and-cytokine-network-crosstalk-in-head-and-n-bb2a8ae48253a93dPharma Surgeen2026-07-25T00:00:00.000ZDNA Repair, Epigenetic Dysregulation, and Cytokine Network Crosstalk in Head and Neck Cancer: Emerging Therapeutic Opportunities and Clinical Trialshttps://www.pharmaradar360.com/article/comparative-analysis-of-clinical-efficacy-safety-and-cosmetic-outcomes-of-modifi-c900e9263336f10aPharma Surgeen2026-07-25T00:00:00.000ZComparative Analysis of Clinical Efficacy, Safety, and Cosmetic Outcomes of Modified Bikini Line Laparoscopic Sleeve Gastrectomy (MBLSG) Versus Standard Laparoscopic Sleeve Gastrectomy (LSG): A Large-Series Studyhttps://www.pharmaradar360.com/article/a-simple-fluorescent-aptasensing-setup-controlled-by-hybridization-chain-reactio-48e8aeb84bc3fbdePharma Surgeen2026-07-25T00:00:00.000ZA Simple Fluorescent Aptasensing Setup Controlled by Hybridization Chain Reaction for Detection of Illegal Drug Methamphetamine: A Future Point-of-Care Testing Assayhttps://www.pharmaradar360.com/article/clinical-and-genetic-spectrum-of-genetic-eye-diseases-seen-in-two-newly-develope-5d2a7bf3a0df8505Pharma Surgeen2026-07-25T00:00:00.000ZClinical and genetic spectrum of genetic eye diseases seen in two newly developed ophthalmic genetics clinics: two-year experiencehttps://www.pharmaradar360.com/article/tamponade-free-superior-ilm-flap-for-idiopathic-macular-hole-repair-a-pilot-stud-20d7493f7a85ab78Pharma Surgeen2026-07-25T00:00:00.000ZTamponade-free superior ILM flap for idiopathic macular hole repair: a pilot studyhttps://www.pharmaradar360.com/article/the-clinical-significance-of-flow-void-absence-following-endoscopic-third-ventri-f82b36d53dff431dPharma Surgeen2026-07-25T00:00:00.000ZThe clinical significance of flow void absence following endoscopic third ventriculostomy in asymptomatic patients: an ISPN-IFNE Surveyhttps://www.pharmaradar360.com/article/a-novel-topical-nitroglycerin-lidocaine-combination-for-procedural-pain-manageme-389fcfa5f504f313Pharma Surgeen2026-07-25T00:00:00.000ZA novel topical nitroglycerin-lidocaine combination for procedural pain management and rapid cannulation in neonates: results from a randomized controlled clinical trialhttps://www.pharmaradar360.com/article/multivariate-control-charts-based-on-mahalanobis-distance-for-bivariate-quality-6be08c229ed5033ePharma Surgeen2026-07-25T00:00:00.000ZMultivariate control charts based on Mahalanobis distance for bivariate quality monitoring in petrochemical and pharmaceutical analyseshttps://www.pharmaradar360.com/article/isorhamnetin-ameliorates-active-ulcerative-colitis-potentially-involving-the-nrf-b49d5a033d50ca46Pharma Surgeen2026-07-25T00:00:00.000ZIsorhamnetin ameliorates active ulcerative colitis potentially involving the Nrf2-PTGS2 axis: an integrative study from clinical evidence mining to in vivo validationhttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-inc-wst-a-bargain-after-7-7-d-e4d21db88236d99bPharma Surgeen2026-07-24T23:39:41.000ZIs West Pharmaceutical Services Inc (WST) a Bargain After 7.7% Dhttps://www.pharmaradar360.com/article/tian-an-pharmaceutical-co-ltd-revenue-breakdown-otc-tnph-907aef5e1f3b57b9Pharma Surgeen2026-07-24T23:39:14.000ZTian'an Pharmaceutical Co., Ltd. Revenue Breakdown – OTC:TNPHhttps://www.pharmaradar360.com/article/kolon-tissuegene-braces-for-100-mn-redemption-calls-on-convertible-bonds-adbca1daa4f87ad2Pharma Surgeen2026-07-24T23:04:44.000ZKolon TissueGene braces for $100 mn redemption calls on convertible bondshttps://www.pharmaradar360.com/article/chugai-pharmaceutical-chgcf-reports-strong-first-half-earnings-381d313f05e9dee4Pharma Surgeen2026-07-24T23:03:45.000ZChugai Pharmaceutical (CHGCF) Reports Strong First Half Earningshttps://www.pharmaradar360.com/article/why-shattuck-labs-stock-flew-nearly-5-higher-on-friday-300c403e91be63dbPharma Surgeen2026-07-24T22:54:32.000ZWhy Shattuck Labs Stock Flew Nearly 5% Higher on Fridayhttps://www.pharmaradar360.com/article/fda-advisers-narrowly-vote-to-add-6-peptides-to-a-drug-compounding-list-what-s-n-05eb0af1ede61b6fPharma Surgeen2026-07-24T22:50:19.000ZFDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?https://www.pharmaradar360.com/article/hims-hers-health-repligen-west-pharmaceutical-services-and-10x-genomics-stocks-t-4134a654a31e5630Pharma Surgeen2026-07-24T22:49:08.000ZHims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Knowhttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-inc-wst-a-bargain-after-7-7-d-15020f1187a22828Pharma Surgeen2026-07-24T22:30:00.000ZIs West Pharmaceutical Services Inc (WST) a Bargain After 7.7% Dhttps://www.pharmaradar360.com/article/us-judge-says-biden-era-restrictions-on-prescribing-abortion-drug-are-unlawful-55a4575a0a7fe2f1Pharma Surgeen2026-07-24T22:25:30.000ZUS judge says Biden-era restrictions on prescribing abortion drug are unlawfulhttps://www.pharmaradar360.com/article/edesa-biotech-inc-revenue-breakdown-nasdaq-edsa-276a4b97bd47b925Pharma Surgeen2026-07-24T22:22:06.000ZEdesa Biotech, Inc. Revenue Breakdown – NASDAQ:EDSAhttps://www.pharmaradar360.com/article/fda-advisers-recommend-relaxing-us-rules-on-compounding-peptides-35c4be0e1373d710Pharma Surgeen2026-07-24T22:14:31.000ZFDA advisers recommend relaxing US rules on compounding peptideshttps://www.pharmaradar360.com/article/vytrus-biotech-sa-revenue-breakdown-tradegate-v5p-c662038a6a9dc0abPharma Surgeen2026-07-24T21:50:28.000ZVytrus Biotech SA Revenue Breakdown – TRADEGATE:V5Phttps://www.pharmaradar360.com/article/baxter-issues-voluntary-nationwide-recall-of-cefazolin-in-dextrose-injection-usp-9a77da71435eb927Pharma Surgeen2026-07-24T21:46:43.000ZBAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTIONhttps://www.pharmaradar360.com/article/veraxa-biotech-shareholders-approve-all-proposals-at-extraordinary-general-meeti-233f990f1ca22f84Pharma Surgeen2026-07-24T21:31:21.000ZVeraxa Biotech Shareholders Approve All Proposals At Extraordinary General Meeting, Strengthening Strategic Flexibility For Future Growthhttps://www.pharmaradar360.com/article/amgen-submits-new-data-to-challenge-fda-s-proposal-to-withdraw-tavneos-5d1a2edec8218146Pharma Surgeen2026-07-24T21:26:44.000ZAmgen submits new data to challenge FDA's proposal to withdraw Tavneoshttps://www.pharmaradar360.com/article/pandora-s-box-fda-peptide-votes-could-open-the-door-to-more-unproven-drugs-4a4937ec5c9035eePharma Surgeen2026-07-24T21:17:44.000Z‘Pandora’s box’: FDA peptide votes could open the door to more unproven drugshttps://www.pharmaradar360.com/article/a-u-s-review-panel-recommended-loosening-restrictions-on-multiple-trendy-peptide-b20546e50de7fff1Pharma Surgeen2026-07-24T20:52:23.000ZA U.S. review panel recommended loosening restrictions on multiple trendy peptides, endorsing proposals that specialized pharmacies be allowed to produce such substances despite alarm bells from medical experts over safety concerns. | via ANC 24/7 Fullhttps://www.pharmaradar360.com/article/amgen-sheds-around-40-staffers-as-struggles-mount-2c09a45f47da405cPharma Surgeen2026-07-24T20:45:34.000ZAmgen sheds around 40 staffers as struggles mounthttps://www.pharmaradar360.com/article/oncolytics-biotech-disclosed-failure-to-satisfy-a-continued-listing-rule-or-stan-3ec9c2085d1baae5Pharma Surgeen2026-07-24T20:43:01.000ZOncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standardhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-underperforms-friday-when-compared-to-com-7e37365bc0be1e2cPharma Surgeen2026-07-24T20:30:00.000ZWest Pharmaceutical Services Inc. stock underperforms Friday when compared to competitorshttps://www.pharmaradar360.com/article/fierce-biotech-hires-russo-as-a-reporter-777dba9874c1511ePharma Surgeen2026-07-24T20:29:33.000ZFierce Biotech hires Russo as a reporterhttps://www.pharmaradar360.com/article/lilly-s-triple-agonist-just-became-its-most-powerful-obesity-drug-yet-3ba531e53c983e04Pharma Surgeen2026-07-24T20:29:30.000ZLilly's triple agonist just became its most powerful obesity drug yethttps://www.pharmaradar360.com/article/veraxa-biotech-shareholders-approve-governance-changes-baee15e8cbaa329bPharma Surgeen2026-07-24T20:26:06.000ZVeraxa Biotech shareholders approve governance changeshttps://www.pharmaradar360.com/article/fda-advisers-say-six-popular-peptides-can-be-compounded-here-are-the-issues-they-d2c956ca89111380Pharma Surgeen2026-07-24T20:26:00.000ZFDA advisers say six popular peptides can be compounded. Here are the issues they considered.https://www.pharmaradar360.com/article/chunghwa-chemical-synthesis-biotech-co-ltd-class-a-revenue-breakdown-twse-1762-0de839250656a084Pharma Surgeen2026-07-24T20:20:48.000ZChunghwa Chemical Synthesis & Biotech Co., Ltd. Class A Revenue Breakdown – TWSE:1762https://www.pharmaradar360.com/article/fugitive-wanted-for-sexual-assault-allegedly-spent-20-years-on-the-run-lived-as-6d30a75d35dd08bcPharma Surgeen2026-07-24T20:00:00.000ZFugitive wanted for sexual assault allegedly spent 20 years on the run, lived as biotech executivehttps://www.pharmaradar360.com/article/ahn-gook-pharmaceutical-co-ltd-revenue-breakdown-krx-001540-01a836770e41879fPharma Surgeen2026-07-24T19:59:39.000ZAHN-GOOK PHARMACEUTICAL Co., Ltd. Revenue Breakdown – KRX:001540https://www.pharmaradar360.com/article/missed-ai-memory-bull-run-biotech-may-be-the-next-breakout-trade-but-retail-sent-671bce17695a553aPharma Surgeen2026-07-24T19:56:28.000ZMissed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lowerhttps://www.pharmaradar360.com/article/conditional-activation-of-il-12-through-a-fibronectin-edb-dependent-switch-gate-479854fd779d8bccPharma Surgeen2026-07-24T19:45:01.000ZConditional activation of IL-12 through a Fibronectin-EDB dependent switch gatehttps://www.pharmaradar360.com/article/assessing-cross-version-simcyp-simulator-prediction-performance-using-a-bioequiv-ae3b629ab3295affPharma Surgeen2026-07-24T19:41:28.000ZAssessing Cross-Version Simcyp Simulator Prediction Performance Using a Bioequivalence Framework to Support EMA Qualificationhttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-enxtpa-dim-stock-faces-rich-p-e-as-margins-improve-to-9-4593c49df4c90465Pharma Surgeen2026-07-24T19:31:36.000ZSartorius Stedim Biotech (ENXTPA:DIM) Stock Faces Rich P/E As Margins Improve To 9.7%https://www.pharmaradar360.com/article/sartorius-stedim-biotech-enxtpa-dim-stock-faces-rich-p-e-as-margins-improve-to-9-927a766da830ae94Pharma Surgeen2026-07-24T19:31:35.000ZSartorius Stedim Biotech (ENXTPA:DIM) Stock Faces Rich P/E As Margins Improve To 9.7%https://www.pharmaradar360.com/article/ono-pharmaceutical-co-ltd-unsponsored-adr-revenue-breakdown-mun-on40-ae1d9a8434feaf9ePharma Surgeen2026-07-24T19:20:29.000ZOno Pharmaceutical Co., Ltd. Unsponsored ADR Revenue Breakdown – MUN:ON40https://www.pharmaradar360.com/article/legend-biotech-shares-fall-after-ubs-downgrade-88bca6cf302a4944Pharma Surgeen2026-07-24T19:16:45.000ZLegend Biotech Shares Fall After UBS Downgradehttps://www.pharmaradar360.com/article/fda-advisers-recommend-against-the-first-unapproved-peptide-on-second-day-of-mee-4b5d13e0f86da78aPharma Surgeen2026-07-24T19:00:39.000ZFDA advisers recommend against the first unapproved peptide on second day of meetinghttps://www.pharmaradar360.com/article/price-to-sales-forward-of-nkgen-biotech-inc-otc-nkgn-ee4b6b0917c55340Pharma Surgeen2026-07-24T18:48:12.000ZPrice to sales forward of NKGen Biotech Inc. – OTC:NKGNhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-nkgen-biotech-inc-otc-nkgn-c19f773049432553Pharma Surgeen2026-07-24T18:47:25.000ZEnterprise value to EBITDA forward of NKGen Biotech Inc. – OTC:NKGNhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-nkgen-biotech-inc-otc-nkgn-3e1e373c01931923Pharma Surgeen2026-07-24T18:45:08.000ZEnterprise value to revenue forward of NKGen Biotech Inc. – OTC:NKGNhttps://www.pharmaradar360.com/article/fda-advisers-recommend-against-the-first-unapproved-peptide-on-second-day-of-mee-7293483178ccda8bPharma Surgeen2026-07-24T18:33:21.000ZFDA advisers recommend against the first unapproved peptide on second day of meetinghttps://www.pharmaradar360.com/article/passaparola-periodo-estivo-2026-sportelli-e-altri-servizi-sempre-aperti-9bb5a19657dfe4aePharma Surgeen2026-07-24T18:30:00.000Z#PASSAPAROLA. Periodo estivo 2026: sportelli e altri servizi sempre apertihttps://www.pharmaradar360.com/article/veraxa-biotech-ag-vrxa-appoints-christoph-erkel-as-chief-scientific-officer-c6b6ebc3313dbb90Pharma Surgeen2026-07-24T18:30:00.000ZVERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officerhttps://www.pharmaradar360.com/article/federal-judge-rules-that-fda-s-mifepristone-restrictions-are-excessive-unscienti-f1ff8549aecf6518Pharma Surgeen2026-07-24T18:27:00.000ZFederal Judge Rules That FDA’s Mifepristone Restrictions Are Excessive, Unscientific and Unlawfulhttps://www.pharmaradar360.com/article/fda-panel-narrowly-backs-peptide-drug-touted-by-joe-rogan-and-other-influencers-40d4e6bdd138a2b9Pharma Surgeen2026-07-24T18:26:00.000ZFDA panel narrowly backs peptide drug touted by Joe Rogan and other influencershttps://www.pharmaradar360.com/article/eastgate-biotech-corp-revenue-breakdown-otc-etbi-5f7ea003a345f30dPharma Surgeen2026-07-24T18:23:21.000ZEASTGATE BIOTECH CORP Revenue Breakdown – OTC:ETBIhttps://www.pharmaradar360.com/article/dhg-pharmaceutical-joint-stock-company-revenue-breakdown-hose-dhg-069f845714d4e09cPharma Surgeen2026-07-24T18:22:21.000ZDHG Pharmaceutical Joint Stock Company Revenue Breakdown – HOSE:DHGhttps://www.pharmaradar360.com/article/us-judge-says-biden-era-restrictions-on-prescribing-abortion-drug-are-unlawful-c72df22b833e9184Pharma Surgeen2026-07-24T18:19:49.000ZUS judge says Biden-era restrictions on prescribing abortion drug are unlawfulhttps://www.pharmaradar360.com/article/fda-approves-tylenol-with-naproxen-otc-b663371cc43691c1Pharma Surgeen2026-07-24T18:08:45.000ZFDA approves Tylenol with Naproxen OTChttps://www.pharmaradar360.com/article/why-is-intellia-therapeutics-ntla-a-battleground-stock-with-38-short-interest-ac440ef295d82fe1Pharma Surgeen2026-07-24T18:07:31.000ZWhy is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interesthttps://www.pharmaradar360.com/article/fda-advisers-dismiss-safety-warnings-back-four-peptide-treatments-ef502c19fa9d7e53Pharma Surgeen2026-07-24T18:00:09.000ZFDA advisers dismiss safety warnings, back four peptide treatmentshttps://www.pharmaradar360.com/article/peptide-adcomm-day-2-emideltide-fails-to-make-grade-in-vote-f9cd9855155110a5Pharma Surgeen2026-07-24T18:00:00.000ZPeptide adcomm Day 2: Emideltide fails to make grade in votehttps://www.pharmaradar360.com/article/american-heart-association-champion-returns-to-lead-board-and-drive-impact-acros-925d48681801ef14Pharma Surgeen2026-07-24T17:58:00.000ZAmerican Heart Association champion returns to lead board and drive impact across the Southeast regionhttps://www.pharmaradar360.com/article/the-american-diabetes-association-applauds-the-preservation-of-medicaid-coverage-e784da1bcfaa4b91Pharma Surgeen2026-07-24T17:52:27.000ZThe American Diabetes Association Applauds the Preservation of Medicaid Coverage for FDA-Approved Obesity Medications in North Carolinahttps://www.pharmaradar360.com/article/mmi-trailblazers-alum-is-a-ray-of-light-at-uno-job-9cfb0b4a771db42ePharma Surgeen2026-07-24T17:48:15.000ZMMI Trailblazers alum is ‘a ray of light’ at UNO jobhttps://www.pharmaradar360.com/article/aurobindo-pharma-inks-licensing-deal-with-merck-for-hiv-drug-741dcc7ecdb35b42Pharma Surgeen2026-07-24T17:38:21.000ZAurobindo Pharma Inks Licensing Deal With Merck For HIV Drughttps://www.pharmaradar360.com/article/de-la-plata-al-mundo-el-satelite-usat-1-de-la-unlp-ya-inicio-su-camino-hacia-el-ff229d860ca5623bPharma Surgeen2026-07-24T17:37:52.000ZDe La Plata al mundo: el satélite USAT 1 de la UNLP ya inició su camino hacia el espaciohttps://www.pharmaradar360.com/article/cordis-project-guide-ai-guiding-your-treatment-with-current-evidence-bca7913ab8edc08fPharma Surgeen2026-07-24T17:36:09.000ZCORDIS project: GUIDE-AI – Guiding your treatment with current evidencehttps://www.pharmaradar360.com/article/cordis-project-regenerative-medicine-and-advanced-medicinal-therapeutic-products-9a0a1aedb4ad104aPharma Surgeen2026-07-24T17:36:04.000ZCORDIS project: Regenerative Medicine and Advanced Medicinal Therapeutic Products United for PhD excellencehttps://www.pharmaradar360.com/article/cordis-project-gender-language-and-epistemicide-in-reproductive-healthcare-01b80c6dfac03767Pharma Surgeen2026-07-24T17:36:02.000ZCORDIS project: Gender, Language and Epistemicide in Reproductive Healthcarehttps://www.pharmaradar360.com/article/mas-infraestructura-para-ciencias-veterinarias-55a5596590f1e9ffPharma Surgeen2026-07-24T17:31:51.000ZMás infraestructura para Ciencias Veterinariashttps://www.pharmaradar360.com/article/estudiantes-ganaron-un-certamen-internacional-de-geociencias-e-ingenieria-fe44871817422c7fPharma Surgeen2026-07-24T17:31:24.000ZEstudiantes ganaron un certamen internacional de geociencias e ingenieríahttps://www.pharmaradar360.com/article/atletas-de-la-unlp-representaran-a-argentina-en-los-juegos-universitarios-americ-6e8cfd07315abafaPharma Surgeen2026-07-24T17:30:52.000ZAtletas de la UNLP representarán a Argentina en los Juegos Universitarios Americanoshttps://www.pharmaradar360.com/article/biotech-companies-are-being-reshaped-by-ai-01b247ca3cd11ed2Pharma Surgeen2026-07-24T17:27:33.000ZBiotech companies are being reshaped by AIhttps://www.pharmaradar360.com/article/chugai-pharmaceutical-revenue-and-profit-surged-in-h1-fy-2026-with-strong-sales-c0967d5df6035606Pharma Surgeen2026-07-24T17:25:20.000ZChugai Pharmaceutical : Revenue and profit surged in H1 FY 2026, with strong sales, robust pipeline, and record filingshttps://www.pharmaradar360.com/article/fda-votes-to-reduce-restrictions-on-four-peptides-pharmexec-e8fcaf5f4f6fa24cPharma Surgeen2026-07-24T17:20:51.000ZFDA Votes to Reduce Restrictions on Four Peptides | PharmExechttps://www.pharmaradar360.com/article/shanghai-fosun-pharmaceutical-group-co-ltd-class-h-revenue-breakdown-fwb-08hh-5f932f3836def0c9Pharma Surgeen2026-07-24T17:20:00.000ZShanghai Fosun Pharmaceutical (Group) Co., Ltd. Class H Revenue Breakdown – FWB:08HHhttps://www.pharmaradar360.com/article/pharmacyte-biotech-inc-revenue-breakdown-nasdaq-pmcb-18c0c5340a0c2344Pharma Surgeen2026-07-24T17:06:03.000ZPharmaCyte Biotech, Inc. Revenue Breakdown – NASDAQ:PMCBhttps://www.pharmaradar360.com/article/zhejiang-east-asia-pharmaceutical-co-ltd-class-a-revenue-breakdown-sse-605177-8b4180074bb87e1bPharma Surgeen2026-07-24T17:05:32.000ZZhejiang East Asia Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SSE:605177https://www.pharmaradar360.com/article/state-policies-on-abortion-coverage-in-medicaid-private-insurance-and-aca-exchan-71a178e829fcff21Pharma Surgeen2026-07-24T17:04:22.000ZState Policies on Abortion Coverage in Medicaid, Private Insurance, and ACA Exchange Plans in 2025https://www.pharmaradar360.com/article/aurobindo-pharma-enters-non-exclusive-license-agreement-with-msd-cf199aeaa0a92ef3Pharma Surgeen2026-07-24T16:49:18.000ZAurobindo Pharma Enters Non-Exclusive License Agreement With MSDhttps://www.pharmaradar360.com/article/veraxa-biotech-ag-nasdaq-vrxa-appoints-christoph-erkel-as-chief-scientific-offic-a838d84d7cec183fPharma Surgeen2026-07-24T16:38:56.000ZVERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officerhttps://www.pharmaradar360.com/article/a-semester-with-work-it-reflections-from-our-assistants-798ae174d8b0482cPharma Surgeen2026-07-24T16:32:01.000ZA Semester with WORK-IT: Reflections from our assistantshttps://www.pharmaradar360.com/article/chugai-pharmaceutical-chgcf-reports-strong-first-half-earnings-5dbcd1332ce12170Pharma Surgeen2026-07-24T16:30:00.000ZChugai Pharmaceutical (CHGCF) Reports Strong First Half Earningshttps://www.pharmaradar360.com/article/african-pharma-giants-secure-deal-for-merck-s-monthly-hiv-pill-b6b078ce7f41c7b7Pharma Surgeen2026-07-24T16:27:17.000ZAfrican pharma giants secure deal for Merck’s monthly HIV pillhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-slides-as-investors-digest-a-post-earnings-surge-e8a0ea9eab203b2bPharma Surgeen2026-07-24T16:25:00.000ZWest Pharmaceutical Services Slides as Investors Digest a Post-Earnings Surgehttps://www.pharmaradar360.com/article/reflections-from-my-phd-improving-the-mental-health-of-young-people-through-earl-d8ce745b23369da5Pharma Surgeen2026-07-24T16:20:25.000ZReflections from my PhD: Improving the mental health of young people through early intervention and preventionhttps://www.pharmaradar360.com/article/parliamentary-health-committee-backs-increased-investment-in-kemri-to-advance-re-c996db0316cf15f0Pharma Surgeen2026-07-24T16:20:19.000ZParliamentary Health Committee Backs Increased Investment in KEMRI to Advance Research and Vaccine Developmenthttps://www.pharmaradar360.com/article/stakeholders-launch-endvl-afrika-project-to-accelerate-elimination-of-visceral-l-60b311a815efa20dPharma Surgeen2026-07-24T16:19:39.000ZStakeholders Launch EndVL Afrika Project to Accelerate Elimination of Visceral Leishmaniasis in East Africahttps://www.pharmaradar360.com/article/aurobindo-pharma-inks-hiv-drug-licensing-deal-with-msd-for-129-countries-d10819f57ddab8e8Pharma Surgeen2026-07-24T16:18:30.000ZAurobindo Pharma inks HIV drug licensing deal with MSD for 129 countrieshttps://www.pharmaradar360.com/article/kemri-hosts-international-investigators-for-the-advancement-of-wash-b-serology-s-4fe0555644db481ePharma Surgeen2026-07-24T16:18:21.000ZKEMRI Hosts International Investigators for the Advancement of WASH-B Serology Studyhttps://www.pharmaradar360.com/article/hims-hers-health-repligen-west-pharmaceutical-services-and-10x-genomics-stocks-t-cc5c298ec20a36d9Pharma Surgeen2026-07-24T16:14:45.000ZHims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Knowhttps://www.pharmaradar360.com/article/inaugural-aacr-d3-opens-with-insights-from-leaders-across-drug-discovery-and-dev-114603a29e830352Pharma Surgeen2026-07-24T16:14:27.000ZInaugural AACR D3 Opens With Insights From Leaders Across Drug Discovery and Developmenthttps://www.pharmaradar360.com/article/fda-cracks-down-on-food-safety-suspends-6-eateries-and-bakeries-in-mumbai-9282637ac2cdab1fPharma Surgeen2026-07-24T16:07:29.000ZFDA cracks down on food safety, suspends 6 eateries and bakeries in Mumbaihttps://www.pharmaradar360.com/article/chugai-pharmaceutical-strong-h1-fy-2026-growth-with-robust-sales-high-filings-an-7ebdfbf869e4c438Pharma Surgeen2026-07-24T16:05:33.000ZChugai Pharmaceutical : Strong H1 FY 2026 growth with robust sales, high filings, and pipeline advances, including AQUA07 Fast Trackhttps://www.pharmaradar360.com/article/ipsen-s-bylvay-fails-phase-3-bold-trial-in-rare-pediatric-liver-disease-4c77182ba8ac2269Pharma Surgeen2026-07-24T16:03:02.000ZIpsen’s Bylvay Fails Phase 3 BOLD Trial In Rare Pediatric Liver Diseasehttps://www.pharmaradar360.com/article/fda-advisers-endorse-legal-path-for-peptides-27369790dfdb17b2Pharma Surgeen2026-07-24T16:00:00.000ZFDA advisers endorse legal path for peptideshttps://www.pharmaradar360.com/article/sls-stock-hits-over-3-year-high-as-aml-drug-trial-nears-final-readout-wall-stree-d690b1c596b74875Pharma Surgeen2026-07-24T15:57:31.000ZSLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upsidehttps://www.pharmaradar360.com/article/boston-globe-biotech-is-back-baby-a-wave-of-life-science-deals-is-pumping-cash-i-32828d3de4b79c5dPharma Surgeen2026-07-24T15:48:33.000ZBoston Globe: Biotech is back, baby! A wave of life science deals is pumping cash into the sector.https://www.pharmaradar360.com/article/the-american-diabetes-association-announces-the-fifth-annual-kiss-a-pig-gala-in-fb078d4f5aa24dbcPharma Surgeen2026-07-24T15:47:26.000ZThe American Diabetes Association Announces the Fifth Annual Kiss a Pig Gala in New Orleanshttps://www.pharmaradar360.com/article/declaration-of-voting-results-by-apichope-pharmaceutical-73c269cf86dc7bf0Pharma Surgeen2026-07-24T15:46:31.000ZDeclaration of Voting Results by ApicHope Pharmaceuticalhttps://www.pharmaradar360.com/article/projet-paddel-laureat-de-l-appel-a-projets-la-donnee-en-sante-environnement-pour-5107169f881a3d64Pharma Surgeen2026-07-24T15:40:06.000ZProjet Paddel, lauréat de l'appel à projets « La donnée en santé - environnement pour la recherche et l'innovation »https://www.pharmaradar360.com/article/sunny-pharmtech-inc-issues-voluntary-nationwide-recall-of-cyclophosphamide-for-i-92af692b5608d384Pharma Surgeen2026-07-24T15:32:20.000ZSunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate Matterhttps://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7Pharma Surgeen2026-07-24T15:30:42.000ZWorking for DHSChttps://www.pharmaradar360.com/article/hims-hers-health-repligen-west-pharmaceutical-services-and-10x-genomics-stocks-t-7caafcf534babc0bPharma Surgeen2026-07-24T15:30:41.000ZHims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Knowhttps://www.pharmaradar360.com/article/hims-hers-health-repligen-west-pharmaceutical-services-and-10x-genomics-stocks-t-a5e3da11c7525f9cPharma Surgeen2026-07-24T15:30:00.000ZHims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Knowhttps://www.pharmaradar360.com/article/shanghai-xiao-fang-pharmaceutical-co-ltd-class-a-revenue-breakdown-sse-603207-31c4c9f9460a45afPharma Surgeen2026-07-24T15:24:20.000ZShanghai Xiao Fang Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SSE:603207https://www.pharmaradar360.com/article/why-geopolitical-supply-chain-mapping-is-critical-for-life-sciences-e53c9e0847141081Pharma Surgeen2026-07-24T15:23:19.000ZWhy Geopolitical Supply Chain Mapping Is Critical for Life Scienceshttps://www.pharmaradar360.com/article/america-is-about-to-go-over-a-peptide-cliff-d438d58afee80737Pharma Surgeen2026-07-24T15:19:59.000ZAmerica Is About to Go Over a Peptide Cliffhttps://www.pharmaradar360.com/article/fda-advisory-committee-meetings-how-they-work-and-why-biotech-stocks-move-c43769af7a6fc3f1Pharma Surgeen2026-07-24T15:13:00.000ZFDA Advisory Committee Meetings: How They Work And Why Biotech Stocks Movehttps://www.pharmaradar360.com/article/here-s-why-you-should-add-cencora-stock-to-your-portfolio-now-8d3151958f033bc6Pharma Surgeen2026-07-24T15:09:00.000ZHere's Why You Should Add Cencora Stock to Your Portfolio Nowhttps://www.pharmaradar360.com/article/medicaid-work-requirements-federal-outreach-requirements-and-state-plans-303d8cf668514aefPharma Surgeen2026-07-24T15:04:47.000ZMedicaid Work Requirements: Federal Outreach Requirements and State Planshttps://www.pharmaradar360.com/article/fda-advisers-weigh-relaxing-rules-on-three-more-peptides-to-widen-access-42d85d35b25a9007Pharma Surgeen2026-07-24T15:00:30.000ZFDA advisers weigh relaxing rules on three more peptides to widen accesshttps://www.pharmaradar360.com/article/another-setback-for-ipsen-s-albireo-portfolio-as-bylvay-flunks-phase-3-trial-0ecf74bc19696f27Pharma Surgeen2026-07-24T15:00:00.000ZAnother setback for Ipsen's Albireo portfolio as Bylvay flunks phase 3 trialhttps://www.pharmaradar360.com/article/fda-side-effects-update-low-blood-sugar-warning-for-xeljanz-rinvoq-and-other-jak-20edb6048df9411aPharma Surgeen2026-07-24T14:59:35.000ZFDA SIDE EFFECTS UPDATE: Low Blood Sugar Warning for Xeljanz, Rinvoq, and other JAK Inhibitorshttps://www.pharmaradar360.com/article/amgen-hands-in-data-package-in-hopes-of-fda-hearing-for-tavneos-defense-f6b317a188bd182ePharma Surgeen2026-07-24T14:50:30.000ZAmgen hands in data package in hopes of FDA hearing for Tavneos defensehttps://www.pharmaradar360.com/article/antibody-drug-conjugates-reported-in-bioray-pharmaceutical-patent-57f9d4b9266e34d2Pharma Surgeen2026-07-24T14:49:53.000ZAntibody-drug conjugates reported in Bioray Pharmaceutical patenthttps://www.pharmaradar360.com/article/chia-tai-tianqing-pharmaceutical-discovers-new-gipr-antagonists-0d4d50bea65efb64Pharma Surgeen2026-07-24T14:49:46.000ZChia Tai Tianqing Pharmaceutical discovers new GIPR antagonistshttps://www.pharmaradar360.com/article/zonsen-peplib-biotech-discloses-new-gpc3-targeting-peptide-drug-conjugates-07dc4aadfe54f851Pharma Surgeen2026-07-24T14:49:32.000ZZonsen Peplib Biotech discloses new GPC3-targeting peptide-drug conjugateshttps://www.pharmaradar360.com/article/the-option-play-of-the-week-nyse-yss-a5bcb6e1eae22e68Pharma Surgeen2026-07-24T14:48:42.000ZThe Option Play Of The Week (NYSE:YSS)https://www.pharmaradar360.com/article/adult-epilepsy-market-to-reach-17-bn-across-7mm-by-2035-315f10aa08797169Pharma Surgeen2026-07-24T14:45:52.000ZAdult epilepsy market to reach $17.bn across 7MM by 2035https://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-eligibility-flow-chart-f228685ceafcee2dPharma Surgeen2026-07-24T14:39:01.000ZMeningococcal B (MenB) time limited vaccination offer: eligibility flow charthttps://www.pharmaradar360.com/article/intermountain-health-primary-children-s-hospital-to-host-mountain-west-stop-of-1-28fd0f50b408f3ecPharma Surgeen2026-07-24T14:35:39.000ZIntermountain Health Primary Children’s Hospital to Host Mountain West Stop of ‘100 Cleft Portraits’ Tour – Free National Traveling Art Exhibit Open to Publichttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-on-fda-acceptance-for-voxzogo-and-the-valuation-cas-e6851c590eb60c9aPharma Surgeen2026-07-24T14:35:31.000ZBioMarin Pharmaceutical (BMRN) On FDA Acceptance For VOXZOGO And The Valuation Casehttps://www.pharmaradar360.com/article/this-little-known-biotech-stock-just-hit-a-new-5-year-high-dbe3532a11c167afPharma Surgeen2026-07-24T14:30:03.000ZThis Little-Known Biotech Stock Just Hit a New 5-Year Highhttps://www.pharmaradar360.com/article/cordis-project-safer-therapeutics-through-early-toxicity-detection-39ef1ddeee037baePharma Surgeen2026-07-24T14:26:32.000ZCORDIS project: Safer Therapeutics Through Early Toxicity Detectionhttps://www.pharmaradar360.com/article/cordis-project-revolutionizing-aml-therapy-a-first-in-class-ck1-inhibitor-for-re-6d70e2056baa0b7cPharma Surgeen2026-07-24T14:26:18.000ZCORDIS project: Revolutionizing AML Therapy - A First-in-Class CK1 Inhibitor for Relapsed Refractory Patientshttps://www.pharmaradar360.com/article/cordis-project-modeling-oncogenesis-phenotypic-identity-and-fate-in-brain-cancer-4970832df6064da5Pharma Surgeen2026-07-24T14:26:16.000ZCORDIS project: Modeling oncogenesis, phenotypic identity and fate in brain cancer avatarshttps://www.pharmaradar360.com/article/cordis-project-enzymatic-stereospecific-rna-phosphorothioate-modification-for-ne-5c35649c5996f1faPharma Surgeen2026-07-24T14:26:15.000ZCORDIS project: Enzymatic STEreospecific RNA phosphorothioate modification for next-generation therapeuticshttps://www.pharmaradar360.com/article/fda-advisers-dismiss-safety-warnings-back-four-peptide-treatments-e5298610714c77b6Pharma Surgeen2026-07-24T14:25:48.000ZFDA Advisers Dismiss Safety Warnings, Back Four Peptide Treatmentshttps://www.pharmaradar360.com/article/fda-warning-letters-highlight-contamination-control-and-facility-maintenance-fai-4edfd5d3386a63ddPharma Surgeen2026-07-24T14:14:36.000ZFDA warning letters highlight contamination control and facility maintenance failureshttps://www.pharmaradar360.com/article/competing-value-signals-impair-reward-learning-via-dopaminergic-mechanisms-and-i-6c10c1ce0b1dbbdcPharma Surgeen2026-07-24T14:00:00.000ZCompeting value signals impair reward-learning via dopaminergic mechanisms and increase explorationhttps://www.pharmaradar360.com/article/cell-type-specific-ca-2-signals-govern-mouse-seminiferous-tubule-physiology-946f26b3a64eeed7Pharma Surgeen2026-07-24T14:00:00.000ZCell type-specific Ca 2+ signals govern mouse seminiferous tubule physiologyhttps://www.pharmaradar360.com/article/asymmetry-in-the-evolution-of-the-male-and-female-germlines-6186ddbf12d71497Pharma Surgeen2026-07-24T14:00:00.000ZAsymmetry in the evolution of the male and female germlineshttps://www.pharmaradar360.com/article/a-desynchrony-mechanism-between-events-triggers-a-compensatory-delay-during-caen-39a2056ea10cf9f8Pharma Surgeen2026-07-24T14:00:00.000ZA desynchrony mechanism between events triggers a compensatory delay during Caenorhabditis elegans developmenthttps://www.pharmaradar360.com/article/republique-democratique-du-congo-8-tonnes-de-medicaments-acheminees-en-ituri-pou-ccf2374280ece631Pharma Surgeen2026-07-24T13:46:13.000ZRépublique démocratique du Congo : 8 tonnes de médicaments acheminées en Ituri pour soutenir la réponse à l'épidémie d'Ebolahttps://www.pharmaradar360.com/article/who-good-manufacturing-practices-for-pharmaceutical-products-main-principles-e3385484b0abc052Pharma Surgeen2026-07-24T13:46:03.000ZWHO good manufacturing practices for pharmaceutical products: Main principleshttps://www.pharmaradar360.com/article/legend-biotech-why-i-m-ready-to-go-long-again-nasdaq-legn-e012ab971e0b5ca9Pharma Surgeen2026-07-24T13:45:09.000ZLegend Biotech: Why I'm Ready To Go Long Again (NASDAQ:LEGN)https://www.pharmaradar360.com/article/ai-helps-stanford-scientists-discover-natural-ozempic-without-the-usual-side-eff-3398d67e3699e262Pharma Surgeen2026-07-24T13:44:43.000ZAI helps Stanford scientists discover “natural Ozempic” without the usual side effectshttps://www.pharmaradar360.com/article/medtronic-tells-remote-workers-living-near-the-twin-cities-to-come-back-to-the-o-a14c60dc4498c22cPharma Surgeen2026-07-24T13:43:23.000ZMedtronic tells remote workers living near the Twin Cities to come back to the officehttps://www.pharmaradar360.com/article/fatal-gene-editing-trial-in-china-raises-ethics-and-oversight-questions-9f5f96101c7e9d3aPharma Surgeen2026-07-24T13:43:06.000ZFatal gene-editing trial in China raises ethics and oversight questionshttps://www.pharmaradar360.com/article/minnesota-teen-cannabis-use-fell-sharply-but-some-groups-still-far-behind-u-of-m-06ca7a4f52b20584Pharma Surgeen2026-07-24T13:42:36.000ZMinnesota teen cannabis use fell sharply, but some groups still far behind, U of M study findshttps://www.pharmaradar360.com/article/gsk-s-first-lung-cancer-approval-a-new-ipo-path-and-more-fbfa0bdbceb47a7cPharma Surgeen2026-07-24T13:42:35.000ZGSK’s first lung cancer approval, a new IPO path and morehttps://www.pharmaradar360.com/article/fatal-gene-editing-trial-in-china-raises-ethics-and-oversight-questions-fb9f1dd1bc9dfe42Pharma Surgeen2026-07-24T13:42:17.000ZFatal gene-editing trial in China raises ethics and oversight questionshttps://www.pharmaradar360.com/article/minnesota-s-boreal-forest-won-t-survive-a-hotter-more-fiery-future-591452d80d6e3873Pharma Surgeen2026-07-24T13:42:06.000ZMinnesota’s boreal forest won’t survive a hotter, more fiery futurehttps://www.pharmaradar360.com/article/guidelines-on-goods-manufacturing-practices-who-a607f79b893edb13Pharma Surgeen2026-07-24T13:41:22.000ZGuidelines on Goods Manufacturing Practices(WHO)https://www.pharmaradar360.com/article/mobile-skin-clinic-expands-dermatologic-care-to-underserved-communities-of-minne-50ad9c87d6175fd3Pharma Surgeen2026-07-24T13:41:12.000ZMobile skin clinic expands dermatologic care to underserved communities of Minnesotahttps://www.pharmaradar360.com/article/beyond-deer-ticks-and-lyme-disease-rare-illnesses-and-tick-biodiversity-0da20cd5f032a368Pharma Surgeen2026-07-24T13:40:34.000ZBeyond deer ticks and Lyme disease: Rare illnesses and tick biodiversityhttps://www.pharmaradar360.com/article/u-studying-zoo-animal-samples-to-find-next-disease-fighting-therapy-c3c5c1b7aa3dd54bPharma Surgeen2026-07-24T13:39:49.000ZU studying zoo animal samples to find next disease-fighting therapyhttps://www.pharmaradar360.com/article/scientists-discover-a-compound-that-could-supercharge-aging-muscle-repair-fb0b6be9905f002cPharma Surgeen2026-07-24T13:37:50.000ZScientists discover a compound that could supercharge aging muscle repairhttps://www.pharmaradar360.com/article/us-fda-peptide-decision-could-create-marketing-challenges-for-beauty-industry-92cab4d1caf22948Pharma Surgeen2026-07-24T13:36:17.000ZUS FDA peptide decision could create marketing challenges for beauty industryhttps://www.pharmaradar360.com/article/guidelines-on-goods-manufacturing-practices-0aac2d8583cc8415Pharma Surgeen2026-07-24T13:32:57.000ZGuidelines on Goods Manufacturing Practiceshttps://www.pharmaradar360.com/article/fortrea-clinical-pharmacology-services-636c4c60b7129349Pharma Surgeen2026-07-24T13:27:39.000ZFortrea clinical pharmacology serviceshttps://www.pharmaradar360.com/article/a-new-antiviral-could-stop-measles-before-an-outbreak-takes-off-a8ae3ed8b737d8b8Pharma Surgeen2026-07-24T13:27:10.000ZA new antiviral could stop measles before an outbreak takes offhttps://www.pharmaradar360.com/article/si-no-57-of-2017-importation-and-exportation-296ddcba426133caPharma Surgeen2026-07-24T13:26:31.000ZSI-No-57-of-2017-Importation-and-Exportationhttps://www.pharmaradar360.com/article/memphis-pharmaceutical-chemical-industries-revenue-breakdown-egx-mpci-50f67176319ab837Pharma Surgeen2026-07-24T13:25:55.000ZMemphis Pharmaceutical & Chemical Industries Revenue Breakdown – EGX:MPCIhttps://www.pharmaradar360.com/article/guidelines-on-application-for-clinical-trial-authorisation-debf0b6bc444a48bPharma Surgeen2026-07-24T13:21:01.000ZGuidelines-on-Application for Clinical Trial Authorisationhttps://www.pharmaradar360.com/article/application-for-grant-of-marketing-authorisation-of-cosmetics-for-use-in-zambia-8471cfe2c03f5470Pharma Surgeen2026-07-24T13:17:30.000ZAPPLICATION-FOR-GRANT-OF-MARKETING-AUTHORISATION-OF-COSMETICS-FOR-USE-IN-ZAMBIAhttps://www.pharmaradar360.com/article/local-executives-to-spearhead-broward-heart-ball-campaign-focused-on-advancing-h-acedc7b644b4640dPharma Surgeen2026-07-24T13:16:00.000ZLocal executives to spearhead Broward Heart Ball campaign focused on advancing heart healthhttps://www.pharmaradar360.com/article/how-specialty-growth-and-cold-chain-demand-are-rewriting-distribution-strategy-89cbdd138b59bd85Pharma Surgeen2026-07-24T13:13:17.000ZHow Specialty Growth and Cold Chain Demand Are Rewriting Distribution Strategyhttps://www.pharmaradar360.com/article/intermountain-health-plans-to-expand-ownership-of-hospitals-and-clinic-operation-b995a139e25950e2Pharma Surgeen2026-07-24T13:13:13.000ZIntermountain Health Plans to Expand Ownership of Hospitals and Clinic Operations Group in Southeast Idahohttps://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-net-asset-value-s-16e81f6701a394fcPharma Surgeen2026-07-24T13:06:00.000ZThe Biotech Growth Trust PLC - Net Asset Value(s)https://www.pharmaradar360.com/article/leeds-clinical-research-unit-cb1664e35a279e61Pharma Surgeen2026-07-24T13:05:24.000ZLeeds clinical research unithttps://www.pharmaradar360.com/article/peptide-l-wave-pcac-approves-four-bulk-drug-substances-for-the-503a-list-847ee4fa87405164Pharma Surgeen2026-07-24T13:04:38.000ZPEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A Listhttps://www.pharmaradar360.com/article/munich-s-biotech-hub-inside-one-of-europe-s-leading-life-sciences-ecosystems-f34bb0d6f57ab6c0Pharma Surgeen2026-07-24T13:03:41.000ZMunich’s biotech hub: Inside one of Europe’s leading life sciences ecosystemshttps://www.pharmaradar360.com/article/fierce-pharma-asia-trump-s-generic-drug-tariffs-samsung-bio-s-1-8b-acquisition-a-ea8383574bbcca37Pharma Surgeen2026-07-24T13:00:00.000ZFierce Pharma Asia—Trump’s generic drug tariffs; Samsung Bio’s $1.8B acquisition; An unusual IPOhttps://www.pharmaradar360.com/article/are-dolphins-the-only-animals-that-call-each-other-by-name-6248721b28059331Pharma Surgeen2026-07-24T12:50:00.000ZAre dolphins the only animals that call each other by name?https://www.pharmaradar360.com/article/can-virtual-humans-transform-drug-discovery-1cb74b0cf561c0fbPharma Surgeen2026-07-24T12:50:00.000ZCan Virtual Humans Transform Drug Discovery?https://www.pharmaradar360.com/article/biotech-etfs-xbi-and-pbe-diverge-sharply-in-str-2590435398ecca27Pharma Surgeen2026-07-24T12:41:56.000ZBiotech ETFs XBI and PBE diverge sharply in str...https://www.pharmaradar360.com/article/the-benefits-of-rapid-topline-pharmacokinetic-pk-data-in-clinical-pharmacology-s-dffff61a1ba38a31Pharma Surgeen2026-07-24T12:34:02.000ZThe benefits of rapid topline pharmacokinetic (PK) data in clinical pharmacology studieshttps://www.pharmaradar360.com/article/drug-packages-get-unique-codes-ridgetech-unit-elected-to-new-role-a041945de2c92a41Pharma Surgeen2026-07-24T12:30:00.000ZDrug packages get unique codes; Ridgetech unit elected to new rolehttps://www.pharmaradar360.com/article/ridgetech-strengthens-pharmaceutical-ecosystem-leadership-with-vice-president-ro-5386dc072a2eecb6Pharma Surgeen2026-07-24T12:30:00.000ZRidgetech Strengthens Pharmaceutical Ecosystem Leadership with Vice-President Role in Zhejiang Biomedical Associationhttps://www.pharmaradar360.com/article/crispr-biotech-scribe-therapeutics-writes-a-new-chapter-with-129m-ipo-d17be9328e1dfc87Pharma Surgeen2026-07-24T12:23:17.000ZCRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPOhttps://www.pharmaradar360.com/article/earnings-call-transcript-bb-biotech-says-q2-portfolio-beat-sector-as-ai-push-adv-549175c1e789630aPharma Surgeen2026-07-24T12:16:35.000ZEarnings call transcript: BB Biotech says q2 portfolio beat sector as ai push advanceshttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-buy-on-lb-pharmaceuticals-stock-ec982c67189aaecdPharma Surgeen2026-07-24T12:16:00.000ZH.C. Wainwright reiterates Buy on LB Pharmaceuticals stockhttps://www.pharmaradar360.com/article/etf-showdown-xbi-vs-pbe-which-biotech-fund-wins-acfb183db60bc583Pharma Surgeen2026-07-24T12:15:52.000ZETF Showdown: XBI vs PBE, Which Biotech Fund Wins?https://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-5d5a454a6cf52b1cPharma Surgeen2026-07-24T12:11:26.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/west-pharmaceutical-delivers-another-beat-but-the-real-story-is-the-mix-shift-ny-75dd5edaeda2ec49Pharma Surgeen2026-07-24T12:08:48.000ZWest Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift (NYSE:WST)https://www.pharmaradar360.com/article/bb-biotech-q2-2026-slides-nav-surges-17-12-new-investments-added-by-investing-co-6b98784ea4f22948Pharma Surgeen2026-07-24T12:02:17.000ZBB Biotech Q2 2026 slides: NAV surges 17%, 12 new investments added By Investing.comhttps://www.pharmaradar360.com/article/ruralrx-summer-interns-train-in-underserved-areas-083cb77c758e736fPharma Surgeen2026-07-24T12:00:12.000ZRuralRx summer interns train in underserved areashttps://www.pharmaradar360.com/article/regeneron-pharmaceuticals-inc-regn-faces-securities-class-action-amid-disclosure-b9b1e6e0254a3b32Pharma Surgeen2026-07-24T12:00:00.000ZRegeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSShttps://www.pharmaradar360.com/article/jubilant-biosys-brings-together-global-biotech-leaders-to-advance-the-future-of-2ae1b2a03ca15e28Pharma Surgeen2026-07-24T12:00:00.000ZJubilant Biosys Brings Together Global Biotech Leaders to Advance the Future of Healthcare Innovation at 2nd EDGE Innovation Forumhttps://www.pharmaradar360.com/article/federal-contracts-for-biotech-opportunities-with-strings-attached-8dd8eae0d14452dbPharma Surgeen2026-07-24T11:58:29.000ZFederal Contracts for Biotech: Opportunities, With Strings Attachedhttps://www.pharmaradar360.com/article/aspen-pharmacare-expands-access-ambitions-for-hiv-prevention-across-africa-throu-e3502bce3241926cPharma Surgeen2026-07-24T11:56:38.000ZAspen Pharmacare expands access ambitions for HIV prevention across Africa through new agreement with MSDhttps://www.pharmaradar360.com/article/bion-biotech-outperformance-fueled-by-m-a-clinical-progress-and-ai-driven-produc-d2b71eb5d8972d08Pharma Surgeen2026-07-24T11:46:53.000ZBION: Biotech outperformance fueled by M&A, clinical progress, and AI-driven productivity gainshttps://www.pharmaradar360.com/article/has-ocugen-s-recent-convertible-notes-offering-stabilized-its-financial-future-24b60403ee69b13dPharma Surgeen2026-07-24T11:39:37.000ZHas Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Futurehttps://www.pharmaradar360.com/article/einzigartige-fusion-fur-ki-gestutzte-prazisionsmedizin-44b81b6a9e85f43ePharma Surgeen2026-07-24T11:34:15.000ZEinzigartige Fusion für KI-gestützte Präzisionsmedizinhttps://www.pharmaradar360.com/article/nih-is-again-terminating-grants-that-the-trump-administration-dislikes-64e33df08c12f465Pharma Surgeen2026-07-24T11:30:00.000ZNIH is again terminating grants that the Trump administration dislikeshttps://www.pharmaradar360.com/article/the-billion-dollar-problem-keeping-ozempic-wegovy-and-zepbound-from-patients-94d8425eed5199c8Pharma Surgeen2026-07-24T11:29:04.000ZThe billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patientshttps://www.pharmaradar360.com/article/establishing-ctdna-as-a-validated-primary-surrogate-endpoint-c7d0ff5bb64441cfPharma Surgeen2026-07-24T11:28:18.000ZEstablishing ctDNA as a validated primary surrogate endpointhttps://www.pharmaradar360.com/article/dronare-med-hjartstartare-i-livraddande-insats-b697aaacab31a250Pharma Surgeen2026-07-24T11:22:09.000ZDrönare med hjärtstartare i livräddande insatshttps://www.pharmaradar360.com/article/q-a-brent-wilhelm-on-supply-chains-and-historical-demand-data-2c65ada0f2708714Pharma Surgeen2026-07-24T11:20:13.000ZQ&A : Brent Wilhelm on Supply Chains and Historical Demand Datahttps://www.pharmaradar360.com/article/is-edgewise-therapeutics-ewtx-on-the-cusp-of-a-breakthrough-year-62f693b42cd85a30Pharma Surgeen2026-07-24T11:11:43.000ZIs Edgewise Therapeutics (EWTX) on the Cusp of a Breakthrough Yearhttps://www.pharmaradar360.com/article/strengthening-partnerships-visibility-and-sustainable-progress-in-the-cdmo-space-03e4e4a255b7a2c2Pharma Surgeen2026-07-24T11:02:21.000ZStrengthening partnerships, visibility and sustainable progress in the CDMO spacehttps://www.pharmaradar360.com/article/97-3f5257d8ec8092f4Pharma Surgeen2026-07-24T11:00:00.000Z「第97回 都市対抗野球大会」組み合わせ決定 日本新薬は鹿嶋市代表「日本製鉄鹿島」と対戦https://www.pharmaradar360.com/article/learning-support-fund-10th-edition-2026-to-2027-01ad8e4272fbaa77Pharma Surgeen2026-07-24T11:00:00.000ZLearning Support Fund 10th edition: 2026 to 2027https://www.pharmaradar360.com/article/learning-support-fund-guidance-eeb00075dd832df4Pharma Surgeen2026-07-24T11:00:00.000ZLearning Support Fund guidancehttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-jp-morgan-keeps-its-buy-rating-6c77dc41fba80d8ePharma Surgeen2026-07-24T10:57:22.000ZSARTORIUS STEDIM BIOTECH : JP Morgan keeps its Buy ratinghttps://www.pharmaradar360.com/article/clinicbarcelona-org-introduces-synth-voice-reading-for-content-and-automated-tra-07e586f7fd6044f2Pharma Surgeen2026-07-24T10:57:00.000ZClínicBarcelona.org introduces synth voice reading for content and automated transcription for videos and podcastshttps://www.pharmaradar360.com/article/merck-strikes-voluntary-licensing-deals-in-poor-countries-for-an-experimental-hi-96e15e1ae63f9fe9Pharma Surgeen2026-07-24T10:48:20.000ZMerck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pillhttps://www.pharmaradar360.com/article/why-playing-with-food-is-a-good-thing-b47cd1b49bb4038aPharma Surgeen2026-07-24T10:45:52.000ZWhy playing with food is a good thinghttps://www.pharmaradar360.com/article/merck-announces-initial-access-plans-for-alimatravir-an-investigational-once-mon-aba69ff2d2127a69Pharma Surgeen2026-07-24T10:45:00.000ZMerck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Developmenthttps://www.pharmaradar360.com/article/merck-announces-initial-access-plans-for-alimatravir-an-investigational-once-mon-37ff38f29e5048eePharma Surgeen2026-07-24T10:45:00.000ZMerck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Developmenthttps://www.pharmaradar360.com/article/merck-inks-landmark-generic-licensing-deal-for-monthly-hiv-pill-05846113f3fc7afbPharma Surgeen2026-07-24T10:45:00.000ZMerck Inks Landmark Generic Licensing Deal for Monthly HIV Pillhttps://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-de-uso-humano-de-julio-de-2026-8b85a535863e0192Pharma Surgeen2026-07-24T10:43:59.000ZReunión del Comité de Medicamentos de Uso Humano de julio de 2026https://www.pharmaradar360.com/article/polypid-azurity-sign-us-330m-deal-for-d-plex100-ddcae2910c7b75dfPharma Surgeen2026-07-24T10:43:25.000ZPolyPid, Azurity Sign US$330M Deal for D-PLEX100https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-26-july-2026-e8a5763a98861b0ePharma Surgeen2026-07-24T10:38:58.000ZWeekly all-cause mortality surveillance: week ending 26 July 2026https://www.pharmaradar360.com/article/requirements-for-the-listing-of-cosmetics-b50405c44df59aebPharma Surgeen2026-07-24T10:36:33.000ZREQUIREMENTS-FOR-THE-LISTING-OF-COSMETICShttps://www.pharmaradar360.com/article/gerresheimer-opens-new-pharmaceutical-glass-packaging-plant-in-china-7edee446fcaf83c8Pharma Surgeen2026-07-24T10:34:07.000ZGerresheimer opens new pharmaceutical glass packaging plant in Chinahttps://www.pharmaradar360.com/article/zamra-cosmetic-guidelines-22mar2023-v-lc-final-1-1c4c940d0275bcb2Pharma Surgeen2026-07-24T10:27:10.000ZZAMRA-Cosmetic-Guidelines-22Mar2023-v.LC-final-1https://www.pharmaradar360.com/article/reg-hikma-pharmaceutical-holding-s-in-company-3684898a71e64634Pharma Surgeen2026-07-24T10:25:35.000ZREG - Hikma Pharmaceutical - Holding(s) in Companyhttps://www.pharmaradar360.com/article/centennial-of-international-summer-school-at-universitat-heidelberg-a9b53b96595a4c71Pharma Surgeen2026-07-24T10:19:12.000ZCentennial of International Summer School at Universität Heidelberghttps://www.pharmaradar360.com/article/is-viking-therapeutics-poised-to-disrupt-the-weight-loss-market-afb5e819ae6f724ePharma Surgeen2026-07-24T10:18:22.000ZIs Viking Therapeutics Poised to Disrupt the Weight-Loss Markethttps://www.pharmaradar360.com/article/api-fpp-assessment-template-loq-v0-zazibona-26fb9f62dadf51adPharma Surgeen2026-07-24T10:16:27.000ZAPI FPP Assessment Template-LOQ_v0 – ZAZIBONAhttps://www.pharmaradar360.com/article/chmp-recommends-eu-approval-of-roche-s-susvimo-the-first-continuous-delivery-tre-2b2b158601dfddecPharma Surgeen2026-07-24T10:15:00.000ZCHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)https://www.pharmaradar360.com/article/active-biotech-doses-first-patient-in-updated-myelofibrosis-study-e7fd295f23d61b38Pharma Surgeen2026-07-24T10:14:40.000ZActive Biotech doses first patient in updated myelofibrosis studyhttps://www.pharmaradar360.com/article/chugai-pharmaceutical-chgcf-reports-strong-first-half-earnings-7fc2c1a3e01a1a96Pharma Surgeen2026-07-24T10:13:49.000ZChugai Pharmaceutical (CHGCF) Reports Strong First Half Earnings